Tango Therapeutics (TNGX) EBITDA Margin (2020 - 2025)

Tango Therapeutics' EBITDA Margin history runs 6 years deep, the most recent figure standing at 26.15% for Q3 2025.

• In Q3 2025, EBITDA Margin rose 30941.0% year-over-year to 26.15%; the TTM figure through Mar 2026 stood at 48.38% (up 30748.0% YoY), while the FY2025 annual figure was 163.03%, up 14635.0% from the prior year.
• EBITDA Margin was 26.15% for Q3 2025 at Tango Therapeutics, up from 1287.87% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 26.15% in Q3 2025 to a low of 1287.87% in Q2 2025.
• Historically, EBITDA Margin has averaged 426.89% across 5 years, with a median of 427.15% in 2022.
• The sharpest annual moves came in 2023 and 2025: EBITDA Margin jumped 30979 bps in 2023, then tumbled 113918 bps in 2025.
• A 5-year view of EBITDA Margin shows it stood at 398.9% in 2021, then retreated by 9 bps to 435.33% in 2022, then slipped by 26 bps to 550.47% in 2023, then plunged by 81 bps to 993.68% in 2024, then soared by 103 bps to 26.15% in 2025.
• The last three EBITDA Margin figures came in at 26.15% (Q3 2025), 1287.87% (Q2 2025), and 788.76% (Q1 2025), per Business Quant data.